Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
AlloNK is currently in clinical trials for systemic lupus erythematosus, patients with or without lupus nephritis, and an investigator-initiated basket trial in multiple autoimmune indications.In July, Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.
7月份，Artiva Biotherapeutics，Inc.（納斯達克股票代碼：ARTV）定價定增了1392萬股，每股12.00美元，募集資金約合1.67億美元。
Artiva is a clinical-stage biotechnology company focused on developing cell therapies for patients with devastating autoimmune diseases and cancers.
Artiva是一家臨床前生物技術公司，專注於開發針對毀滅性自身免疫性疾病和癌症患者的細胞療法。
Artiva's lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion.
Artiva的主導項目AlloNk是一種異基因、非基因修飾、冷凍保存的NK細胞療法候選，旨在增強單克隆抗體的抗體依賴性細胞毒作用，進一步驅動B細胞減少。
AlloNK is currently in clinical trials for systemic lupus erythematosus, patients with or without lupus nephritis, and an investigator-initiated basket trial in multiple autoimmune indications.
AlloNk目前在系統性紅斑狼瘡、有或沒有腎小球腎炎的患者以及多種自身免疫疾病的調查者發起試驗中。
Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers.
Artiva的管線還包括針對實體瘤和血液系統癌症的CAR-Nk候選藥物。
Needham initiates coverage on Artiva and says, "Artiva is developing what we view as scalable cellular therapeutics for autoimmune disorders."
Needham開始關注Artiva並表示：「Artiva在開發我們認爲可擴展的自身免疫性疾病細胞療法。」
Needham notes that initial clinical results from the lupus study are expected in 2025, most probably in the first half of 2025. The analyst also sees AlloNK in lupus as the main near-term driver for Artiva.
Needham指出，紅斑狼瘡研究的初步臨床結果預計將在2025年公佈，很可能在2025年上半年公佈。分析師還認爲，AlloNk在紅斑狼瘡方面是Artiva的主要近期驅動器。
A Needham analyst estimates that AlloNK could achieve approximately $1.7 billion in global sales for treating systemic lupus erythematosus (SLE) and lupus nephritis (LN) by 2038, capturing around 20% of the market. The analyst also notes that several other companies are developing cellular therapies for SLE and LN, including other NK cell programs.
Needham分析師估計，到2038年，對於治療系統性紅斑狼瘡（SLE）和腎小球腎炎（LN），AlloNk的全球銷售額可能達到大約17億美元，佔據20%的市場份額。分析師還指出，其他幾家公司也在開發針對SLE和LN的細胞療法，包括其他NK細胞項目。
Needham has initiated with a Buy rating and a price target of $23.
Needham給予買入評級和23美元的目標價。
Wedbush also initiated coverage on Artiva Biotherapeutics, noting that the company's cell therapy is straightforward to manufacture and deliver and adaptable to different targets.
Wedbush也開始關注Artiva Biotherapeutics，指出該公司的細胞療法易於製造和交付，並且適用於不同的治療目標。
Recent studies have confirmed that various cell-based therapies are effective for different autoimmune conditions, showing a link between B-cell depletion and symptom improvement.
最近的研究證實，不同的細胞治療對於不同的自身免疫疾病是有效的，顯示出B細胞減少與症狀改善之間的關聯。
Wedbush initiated with an Outperform rating with a price target of $18.
Wedbush以超額表現的評級和18美元的目標價開始覆蓋。
"Given the level of B-cell depletion achieved in Artiva's B-NHL study, we believe AlloNK has the potential to drive deep and durable remissions in B-cell dependent autoimmune diseases," Wedbush analyst added.
Wedbush分析師補充說：「考慮到Artiva的b-NHL研究中實現的B細胞減少程度，我們認爲AlloNk具有在B細胞依賴性自身免疫性疾病中推動深度和持久性緩解的潛力。」
Price Action: ARTV stock is down 0.36% at $11.18 at last check Tuesday.
股票價格：截至最後交易日週二，ARTV股票下跌0.36%，至11.18美元。
Photo via Shutterstock
圖片來自shutterstock。
- Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug.
- 法官裁定，諾華製藥阻止其暢銷心臟病藥物仿製藥的推出的努力失敗。
